Lithium, Serum
Use
Monitoring therapy of patients with bipolar disorders, including recurrent episodes of mania and depression. Evaluating lithium toxicity. Lithium is known to alter intraneuronal metabolism of catecholamines, and it is used to suppress the manic phase of manic-depressive psychosis. Regular monitoring is essential due to associated toxicities caused by lithium accumulation ataxia, slurred speech, and confusion.
Special Instructions
Not provided.
Limitations
Concentration of lithium in serum varies with time post-dose, necessitating standardized blood draw times. Various medications and supplements could interfere with lithium levels. Conditions like salt and water loss can exacerbate side effects or lithium concentrations.
FDA ApprovedNew York Approved
Methodology
Automated Analyzer (Clinical Chemistry)
Biomarkers
Lithium
Analyte
LOINC Codes
- 14334-7 - Lithium SerPl-sCnc
- 14334-7 - Lithium SerPl-sCnc
Result Turnaround Time
0-1 day
Related Documents
For more information, please review the documents below
Specimen
Serum
Volume
0.5 mL
Minimum Volume
0.25 mL
Container
Plastic vial
Collection Instructions
Draw blood 8 to 12 hours after last dose (trough specimen). Serum gel tubes should be centrifuged within 2 hours of collection. Red-top tubes should be centrifuged and the serum aliquoted into a plastic vial within 2 hours.
Causes for Rejection
Gross hemolysis
Stability Requirements
| Temperature | Period |
|---|---|
| Room Temperature | 72 hours |
| Refrigerated | 7 days |
| Frozen | 28 days |